ClinicalTrials.gg
CompletedNCT04754854Updated Nov 16, 2026

Reduction of Blood Recirculation in Veno-Venous ECMO

An observational study in Extracorporeal Membrane Oxygenation and Acute Respiratory Distress Syndrome, sponsored by Charite University, Berlin, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Charite University, Berlin, Germany · Observational

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
77
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.

Enrollment
14th of 21
77 · median 132
Started
2020
with 12 others
Observational
22 of 48
2 open now
Registered
36th of 48
by date
Lead sponsor
4 of 48
Charite University, Berlin, Germany

Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 14th largest by enrollment of the 21 observational ones that give a count, is one of 13 that started in 2020, is one of 22 observational ones, and was the 36th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Respiratory Distress Syndrome with a site in Germany, or all of them as a file.
02

Study summary

Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.

A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.

ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.

Read the detailed description

Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.

03

Conditions studied

  • Extracorporeal Membrane Oxygenation
  • Acute Respiratory Distress Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Inclusion Criteria:

  • patients aged 18 years or older
  • ARDS
  • veno-venous ECMO

Exclusion Criteria:

  • age \< 18 years
  • hemodynamic instability during measurement of recirculation
  • pregnancy
  • inability to obtain patient's consent or consent of legal guardian

Eligibility criteria

Patients aged 18 years or older requiring veno-venous ECMO for treatment of hypoxemia in ARDS.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
77 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Successful ECMO blood flow reduction

    Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction

    Time frame: Once within the first week after initiation of ECMO therapy

Secondary outcomes

  1. Recirculation fraction

    Fraction of blood recirculating through the ECMO circuit

    Time frame: Once within the first week after initiation of ECMO therapy

  2. Arterial blood oxygen content

    Arterial blood oxygen content before vs. after reduction of ECMO blood flow

    Time frame: Once within the first week after initiation of ECMO therapy

  3. Extracorporeal blood Flow

    ECMO Blood Flow before vs. after reduction of ECMO blood flow

    Time frame: Once within the first week after initiation of ECMO therapy

  4. Extracorporeal gas flow

    ECMO Sweep Gas flow

    Time frame: Once within the first week after initiation of ECMO therapy

  5. Length of ECMO therapy

    Days on ECMO

    Time frame: Daily until the end of ECMO therapy (approximately 14 days)

  6. Cannula position and distance

    The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans)

    Time frame: Once within the first week after initiation of ECMO therapy

  7. Right heart dysfunction

    Existing echocardiography will be evaluated for possible right heart dysfunction

    Time frame: Once within the first week after initiation of ECMO therapy

  8. Length of mechanical ventilation

    Length of mechanical ventilation

    Time frame: Entire duration of the ICU stay (approximately 28 days)

  9. Complications of ECMO therapy

    Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis

    Time frame: Length of ECMO therapy (approximately 14 days)

  10. ICU mortality

    ICU mortality

    Time frame: Entire duration of the ICU stay (approximately 28 days)

  11. ICU length of stay

    ICU length of stay

    Time frame: Entire duration of the ICU stay (approximately 28 days)

  12. Incidence of ICU-acquired organ dysfunctions and complications

    Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections

    Time frame: Entire duration of the ICU stay (approximately 28 days)

  13. ECMO blood flow over time

    ECMO blood and sweep gas flow over time

    Time frame: Daily until the end of ECMO therapy (approximately 14 days)

  14. ECMO sweep gas flow over time

    ECMO sweep gas flow over time

    Time frame: Daily until the end of ECMO therapy (approximately 14 days)

  15. Mobility at ICU discharge

    Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently)

    Time frame: Discharge from the ICU (approximately 28 days)

  16. Weaning level at ICU discharge

    Level of weaning reached at ICU discharge

    Time frame: Discharge from the ICU (approximately 28 days)

  17. Status of mechanical ventilation at ICU discharge

    Status of mechanical ventilation at ICU discharge including all relevant settings and parameters

    Time frame: Discharge from the ICU (approximately 28 days)

  18. Level of organ dysfunction at ICU discharge

    Sepsis-related Organ Failure Assessment Score at ICU discharge

    Time frame: Discharge from the ICU (approximately 28 days)

  19. Level of consciousness at ICU discharge

    Glasgow Coma Scale at ICU discharge

    Time frame: Discharge from the ICU (approximately 28 days)

  20. Level of disease severity

    Acute Physiology And Chronic Health Evaluation at ICU discharge

    Time frame: Discharge from the ICU (approximately 28 days)

  21. Hospital acquired infections related to ECMO therapy

    Infection/colonisation of the ECMO circuit

    Time frame: Entire duration of ECMO therapy

  22. Bleeding and thrombembolic complications of ECMO therapy

    Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit

    Time frame: Entire duration of ECMO therapy

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in May 2026, 65 months.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 65 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → May 2026 and completion Oct 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Feb 15, 2021
StartActual
Nov 20, 2020
Primary completionActual
May 5, 2026was Aug 2026
CompletionActual
May 5, 2026was Oct 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 16, 2026
Sites
1 site added, 1 site removed
Show site
  • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum · Berlin, Germany
Show 1 removed
  • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum · Berlin, Germany
Nov 16, 2026
Primary completion
Aug 31, 2026→May 5, 2026 (actual)
Nov 16, 2026
Study completion
Oct 31, 2026→May 5, 2026 (actual)
Nov 16, 2026
Enrollment
136 (estimated)→77 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum · Berlin, Germany
    Show 1 removed
    • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum · Berlin, Germany
    Primary completion Aug 31, 2026→May 5, 2026 (now actual)
    Study completion Oct 31, 2026→May 5, 2026 (now actual)
    Enrollment 136 (estimated)→77 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04754854
Responsible party
Steffen Weber-Carstens (Prof. Dr. med., Charite University, Berlin, Germany) — Principal investigator
First posted
Feb 15, 2021
Start date
Nov 20, 2020
Primary completion
May 5, 2026
Completion
May 5, 2026
Last update
Nov 16, 2026

Study contacts

Martin Russ, Dr. med.
principal investigator · Charite University Hospital Berlin
Philipp A Pickerodt, Dr. med.
principal investigator · Charite University Hospital Berlin
Vladimir Skrypnikov, Dr. med.
principal investigator · Charite University Hospital Berlin
Steffen Weber-Carstens, Prof. Dr. med.
principal investigator · Charite University Hospital Berlin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion